fda deadline for compounded semaglutide crackdown on off-brand Ozempic products set to take effect, threatening supply and access many Makers of compounded Wegovy, Ozempic

& Lwik, D

Adverse events, including hospitalizations, were reported after patients incorrectly measured out the medication, with some individuals reportedly injecting themselves with ten times the prescribed dose

Weight loss can vary widely among individuals, but many people lose between 5% to 10% of their body weight over six months to a year

The GLP-1 Market: A Booming Opportunity: GLP-1-based therapies have emerged as promising treatments for obesity and diabetes, offering significant weight loss benefits and improved glycemic control

Semaglutide holds a 42% share of the GLP-1 Obesity Home Delivery Injectables Market due to its strong clinical performance, broad regulatory approvals, and patient-friendly dosing regimen